Navigation Links
RainDance Appoints Becker Chief Commercial Officer
Date:3/18/2008

GUILFORD, Conn., March 18 /PRNewswire/ -- RainDance Technologies, Inc., a developer of NanoReactor droplet-based microfluidic technology, today announced the appointment of Stephen E. Becker as Vice President, Commercial Officer, effective immediately.

"Mr. Becker will be responsible for continuing the growth of the company's commercial operations as it prepares for the launch of its first life science offering," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "These duties will include the continued development of the sales channels, leading customer service and support programs, and development of the strategic marketing plan."

The RainDance platform combines emulsion-based droplets and microfluidics to enable a host of existing applications in the company's nano-scale format, including genomic analysis, cell-based assays, and single molecule detection. Samples such as cells, nucleic acids, proteins, beads, and chemical compounds are encapsulated in individual micron-sized droplets on assay-specific microfludic chips. Since each droplet is the equivalent of a well in a microtiter plate, the RainDance platform can process and analyze up to 10,000 samples per second with unparalleled accuracy.

Becker joins RainDance from Agilent Technologies, where he served as Senior Sales Manager in the company's Americas Field Operations. There, he led the commercial introduction of novel genetic and epigenetic microarray assays that achieved over 20% growth rates in 2006 and 2007 in the research and molecular diagnostics markets. At GE Healthcare (formerly Amersham Pharmacia Biotech), Becker held several senior management assignments, including Director, Gene and Protein Discovery, and Director, Business Support. He also held sales management positions at Spectrum Chemical Manufacturing Corporation and Curtin Matheson Scientific, Inc. Becker received a bachelor's degree in biology from St. Mary's College of California
'/>"/>

SOURCE RainDance Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. RainDance Technologies Appoints McNary President and CEO
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...s been met for patients with advanced-stage, or... Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris...a global biopharmaceutical company focused on endo...ve efficacy data from a Phase 2 study with its tar...rly AN-152), in patients with advanced or recurren...
(Date:11/24/2009)...wswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (... is scheduled to present at the Piper Jaffray 21st... at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Tim...Jack Lief, Arena,s President and Chief Executive O... company, including its clinical development and d...
(Date:11/24/2009)...tomers with Partners Validated to Process and Anal... Ottawa, ON (PRWEB) Novemb...f products for biological sample collection, stabi...global partner program. The program offers signifi...ity and is designed to help partners scale and dif...
(Date:11/23/2009)...tive new study, a University of Utah scientist arg...r cause of global warming cannot be stabilized un...ds the equivalent of one new nuclear power plant e...e any substantial near-term departure from recentl... rates," says the new paper by Tim Garrett, an ass...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4
...iences,(Nasdaq: MATK ) announced today the launch...s patented, vegetarian form of DHA omega-3 for bra...bread with vegetarian DHA,Oroweat 9 Grain Bread wi...ble at major retailers in the Pacific Northwest, C...from Bimbo Bakeries demonstrates the broad range o...
...ernational Inc. (NYSE: BAX ) announced today that...e of an additional $2 billion of the company,s,com...mpany,s existing share,repurchase authorization., ...thorization under its,previous $2 billion share re.... Shares will be repurchased in the open market at...
...es Therapeutics,Inc. (Nasdaq: TPTX ) today announ... muscarinic agonist in development for xerostomia,...he company is conducting a randomized, double-blin...n square design to evaluate,the safety, tolerabili...ximately 24 patients will be enrolled at three sit...
Other Biology Technology:Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
(Date:11/24/2009)...s to understanding how sounds associated with Navy... or if they hear it at all. , The same type of ...es to detect flaws in the space shuttle,s behemoth...peek inside the giant head of a whale. The scans a...f a whale,s hearing anatomy using a breakthrough m...
(Date:11/24/2009)...kable class of ring-shaped protein motors has been...ey National Laboratory (Berkeley Lab) using a stat...he Advanced Light Source (ALS). These protein moto...cation, and are vital to the survival of all biolo... the human papillomavirus, which has been linked t...
(Date:11/24/2009)... held secrets of the earth,s history locked in its...ry little information on the environments that hav... years. Now, a team of researchers from nine insti...ne of $10 million dollars by the National Science ... literally. These scientists will drill through t...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4LSU gets to the bottom of things -- in Antarctica 2Researchers begin to decipher metabolism of sexual assault drug 10831 1Researchers begin to decipher metabolism of sexual assault drug 10831 2Leahy Will Vote to End Health Bill Filibuster Plans to Offer Amendment to End Health Insurers Antitrust Exemption 61782 1Warner Chilcott Prices Secondary Equity Offering 6425 1Warner Chilcott Prices Secondary Equity Offering 6425 2Warner Chilcott Prices Secondary Equity Offering 6425 3Warner Chilcott Prices Secondary Equity Offering 6425 4
...can Society for Microbiology (ASM) Siemens Healthc...presented to Adrian M. Zelazny, Staff Scientist, L...National Institutes of Health (NIH). This award re...microbiology or antimicrobial therapy. , Dr. Zela...ceptibility and resistance, microbial virulence, a...
...ion of biosolids (treated municipal sewage sludge)... source of plant nutrients and organic matter. How... in biosolids led to concerns that farmland applic...l and their subsequent translocation through the h...ns have extremely high bioaccumulation potential. ...
...c and professional organization of more than 16,00...lications, technology and science of molecular ima...esearch grants to support molecular imaging resear...esearch Foundation, represent the society,s commit... supporting the next generation of researchers. ,...
Other Biology News:Dioxin risk in soil and plant tissues after long-term biosolids application 2SNM awards $300,000 to support molecular imaging research 2
...0 (CYP450) metabolite postulated to play an autaco...rat cerebral microvessels, 20-HETE is a vasoconstr...y vasoconstriction. 20-HETE is excreted mainly as ...ee 20-HETE (20-40 pg/ml in human urine) is about 1...
...m enables you to insert a transposable element of ... transposition. It uses TnsABC* Transposase to ins... target. Target DNA may be a plasmid, cosmid, BAC ...nterests (6-8). If the insertion site is within a ...
Peptide Standards from New England Biolabs
CORNING CELLSTACK VENTED CAP, 33MM, STERILE, 0.2UM MEMBRANE from Sigma-Aldrich
Biology Products: